Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability
Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance
List view / Grid view
Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance
PhRMA report highlights the healthy nature of the US biopharmaceuticals industry, which invests about $75bn annually in research and development and supports nearly 4.7m jobs across the country
New ISPE guidance provides a scientific, risk-based approach for managing cross-contamination risk within shared facilities ...
SecurMed UK, the UK Medicines Verification Organisation, is entering into a Letter of Intent with Arvato Systems as its IT blueprint service provider.
Digital risk calculator highlights cyber attacks and highly sensitive or valuable data as major risks for life sciences businesses
David Edwards explains how Agilent spectroscopy systems combine core qualities of robustness and reliability with a spirit of innovation.
Dr Steven Baertschi has joined the editorial advisory board of European Pharmaceutical Review.